<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="molecules-24-01552-t002" orientation="portrait" position="float">
 <object-id pub-id-type="pii">molecules-24-01552-t002_Table 2</object-id>
 <label>Table 2</label>
 <caption>
  <p>Preclinical studies of silymarin and derivatives in vivo.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Substrate(s)</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Analysis/Model</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route of Administration</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Legalon
     <sup>®</sup> SIL
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV infection of uPA-SCID-chimeric mice with humanized livers</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Legalon
     <sup>®</sup> SIL blocked HCV production and increased anti-inflammatory and anti-proliferative gene expressions without affecting serum albumin levels
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B16-molecules-24-01552" ref-type="bibr">16</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IAV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silybin derivatives (S0 and S3)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IAV infection of BALB/c mice</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S0 and S3 increased the survival rate of mice (40% and 60% respectively), and S3 decreased virus titers in the lungs (100-fold)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B23-molecules-24-01552" ref-type="bibr">23</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silymarin</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBV X protein
     <break/>(HBx) transgenic mice
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silymarin had no effect on HBx expression and late stage carcinogenesis, but recovered fatty acid change and liver pathology in the early stages of liver damage</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B32-molecules-24-01552" ref-type="bibr">32</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
